JP2023181255A5 - - Google Patents

Download PDF

Info

Publication number
JP2023181255A5
JP2023181255A5 JP2023179310A JP2023179310A JP2023181255A5 JP 2023181255 A5 JP2023181255 A5 JP 2023181255A5 JP 2023179310 A JP2023179310 A JP 2023179310A JP 2023179310 A JP2023179310 A JP 2023179310A JP 2023181255 A5 JP2023181255 A5 JP 2023181255A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023179310A
Other languages
Japanese (ja)
Other versions
JP2023181255A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/031858 external-priority patent/WO2019217916A1/en
Application filed filed Critical
Publication of JP2023181255A publication Critical patent/JP2023181255A/ja
Publication of JP2023181255A5 publication Critical patent/JP2023181255A5/ja
Pending legal-status Critical Current

Links

JP2023179310A 2018-05-10 2023-10-18 疾病の予後と管理のための方法 Pending JP2023181255A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862669915P 2018-05-10 2018-05-10
US62/669,915 2018-05-10
PCT/US2019/031858 WO2019217916A1 (en) 2018-05-10 2019-05-10 Methods for prognosis and management of disease
JP2020563696A JP7371019B2 (ja) 2018-05-10 2019-05-10 疾病の予後と管理のための方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020563696A Division JP7371019B2 (ja) 2018-05-10 2019-05-10 疾病の予後と管理のための方法

Publications (2)

Publication Number Publication Date
JP2023181255A JP2023181255A (ja) 2023-12-21
JP2023181255A5 true JP2023181255A5 (https=) 2024-03-06

Family

ID=66655475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563696A Active JP7371019B2 (ja) 2018-05-10 2019-05-10 疾病の予後と管理のための方法
JP2023179310A Pending JP2023181255A (ja) 2018-05-10 2023-10-18 疾病の予後と管理のための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020563696A Active JP7371019B2 (ja) 2018-05-10 2019-05-10 疾病の予後と管理のための方法

Country Status (8)

Country Link
US (1) US20210231686A1 (https=)
EP (1) EP3791188A1 (https=)
JP (2) JP7371019B2 (https=)
KR (1) KR20210014109A (https=)
CN (1) CN112424608A (https=)
AU (1) AU2019264996A1 (https=)
IL (1) IL278616B2 (https=)
WO (1) WO2019217916A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309046B2 (en) 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
CN113842449B (zh) * 2021-09-08 2024-02-23 乐卫东 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用
WO2025049671A1 (en) * 2023-08-30 2025-03-06 The Methodist Hospital Markers of amyotrophic lateral sclerosis survival and uses thereof
WO2025058005A1 (ja) * 2023-09-15 2025-03-20 国立大学法人徳島大学 筋萎縮性側索硬化症(als)と関連するバイオマーカー

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US20050130320A1 (en) 2000-11-09 2005-06-16 George Shaji. T. Method for identifying the proteome of cells using an antibody library microarray
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
US6800453B2 (en) 2001-01-23 2004-10-05 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
WO2003062444A2 (en) 2001-11-13 2003-07-31 Emory University Array systems and methods
JP2005510524A (ja) * 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
AU2003224674A1 (en) 2002-03-11 2003-09-29 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
WO2005020784A2 (en) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
ES2406266T3 (es) * 2004-05-11 2013-06-06 Mochida Pharmaceutical Co., Ltd. Antígeno CD14 soluble novedoso
WO2010102412A1 (en) * 2009-03-11 2010-09-16 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
EP2501720A2 (en) * 2009-11-18 2012-09-26 Lascco SA Ifn inhibitors in the treatment of motoneuron diseases
WO2011111043A1 (en) * 2010-03-10 2011-09-15 Yeda Research And Development Co. Ltd Cellular blood markers for early diagnosis of als and for als progression
WO2012004276A2 (en) * 2010-07-06 2012-01-12 Fondazione Telethon Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
US9506923B2 (en) * 2011-08-12 2016-11-29 Lsi Medience Corporation Method of diagnosing surgical site infections
US10184151B2 (en) * 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
WO2014102333A1 (en) * 2012-12-28 2014-07-03 Mitsubishi Chemical Medience Corporation Use of scd14 or its fragments or derivatives for risk stratisfaction, diagnosis and prognosis
EP3142674A4 (en) * 2014-05-16 2018-01-17 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
WO2016083374A1 (en) * 2014-11-25 2016-06-02 F. Hoffmann-La Roche Ag Biomarkers of fast progression of chronic kidney disease
HK1250012A1 (zh) * 2015-04-02 2018-11-23 The Methodist Hospital System 基於多孔硅微粒的癌症疫苗及增强抗肿瘤免疫的方法
US10724095B2 (en) * 2015-12-16 2020-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
WO2017147378A1 (en) * 2016-02-25 2017-08-31 The Trustees Of Columbia University In The City Of New York Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
IL309046B2 (en) 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Similar Documents

Publication Publication Date Title
JP2023181255A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001987A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR102022017795A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307050157S (https=)
BY13166U (https=)
CN307045570S (https=)
CN307044376S (https=)
CN307044316S (https=)
CN307044315S (https=)